IL34513A - Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one compounds and methods for their production - Google Patents
Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one compounds and methods for their productionInfo
- Publication number
- IL34513A IL34513A IL34513A IL3451370A IL34513A IL 34513 A IL34513 A IL 34513A IL 34513 A IL34513 A IL 34513A IL 3451370 A IL3451370 A IL 3451370A IL 34513 A IL34513 A IL 34513A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- ethyl
- diazepin
- reaction
- benzoyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 37
- 238000004519 manufacturing process Methods 0.000 title description 3
- UFPRICAHETWYEQ-UHFFFAOYSA-N 1H-pyrazolo[3,4-e][1,4]diazepin-7-one Chemical class O=C1C=NC=C2C=NNC2=N1 UFPRICAHETWYEQ-UHFFFAOYSA-N 0.000 title 1
- -1 3-Ethyl- - ( o-fluorophenyl) Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 71
- 239000000203 mixture Substances 0.000 description 69
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 58
- 239000000243 solution Substances 0.000 description 56
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 238000002425 crystallisation Methods 0.000 description 52
- 230000008025 crystallization Effects 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 239000007787 solid Substances 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 33
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 238000010992 reflux Methods 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 22
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 20
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229960000443 hydrochloric acid Drugs 0.000 description 11
- 235000011167 hydrochloric acid Nutrition 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- AXXNMFMZZSYXSN-UHFFFAOYSA-N 2h-pyrazolo[4,3-c]diazepin-3-one Chemical class C1=CC=NN=C2C(=O)NN=C21 AXXNMFMZZSYXSN-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 9
- 235000010446 mineral oil Nutrition 0.000 description 9
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 8
- 229960004592 isopropanol Drugs 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 238000007429 general method Methods 0.000 description 7
- 238000007363 ring formation reaction Methods 0.000 description 7
- RHZBRCQIKQUQHQ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetyl chloride Chemical compound C1=CC=C2C(=O)N(CC(=O)Cl)C(=O)C2=C1 RHZBRCQIKQUQHQ-UHFFFAOYSA-N 0.000 description 6
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical group CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 6
- 150000003217 pyrazoles Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- ROLLNLXXOVULIM-UHFFFAOYSA-N 1,2-dihydrodiazepin-3-one Chemical class O=C1NNC=CC=C1 ROLLNLXXOVULIM-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- IJPFBRONCJOTTA-UHFFFAOYSA-N 5-chloro-1h-pyrazole Chemical compound ClC1=CC=NN1 IJPFBRONCJOTTA-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 230000000049 anti-anxiety effect Effects 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000006332 fluoro benzoyl group Chemical group 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 4
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960004782 chlordiazepoxide Drugs 0.000 description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 239000002027 dichloromethane extract Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000003511 tertiary amides Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- NWFRMQLOBKDVHG-UHFFFAOYSA-N (5-chloro-1-methyl-3-propylpyrazol-4-yl)-(2-chlorophenyl)methanone Chemical compound ClC1=C(C(=NN1C)CCC)C(C1=C(C=CC=C1)Cl)=O NWFRMQLOBKDVHG-UHFFFAOYSA-N 0.000 description 2
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 2
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 2
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012022 methylating agents Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- XCJMRDDECHBZQP-UHFFFAOYSA-N (3-aminophenyl)-(1,3-dimethylpyrazol-4-yl)methanone Chemical compound CC1=NN(C)C=C1C(=O)C1=CC=CC(N)=C1 XCJMRDDECHBZQP-UHFFFAOYSA-N 0.000 description 1
- LNYHSCBGKWCAME-UHFFFAOYSA-N (5-amino-1,3-dimethylpyrazol-4-yl)-(2-chlorophenyl)methanone Chemical compound CC1=NN(C)C(N)=C1C(=O)C1=CC=CC=C1Cl LNYHSCBGKWCAME-UHFFFAOYSA-N 0.000 description 1
- LMBRFPRUZRLJAW-UHFFFAOYSA-N (5-amino-1,3-dimethylpyrazol-4-yl)-(2-fluorophenyl)methanone Chemical compound CC1=NN(C)C(N)=C1C(=O)C1=CC=CC=C1F LMBRFPRUZRLJAW-UHFFFAOYSA-N 0.000 description 1
- KZBRSFGNHQCVPX-UHFFFAOYSA-N (5-amino-3-ethyl-1-methylpyrazol-4-yl)-(2-chlorophenyl)methanone Chemical compound CCC1=NN(C)C(N)=C1C(=O)C1=CC=CC=C1Cl KZBRSFGNHQCVPX-UHFFFAOYSA-N 0.000 description 1
- CGUWCWRVSCYBGD-UHFFFAOYSA-N (5-amino-3-ethyl-1-methylpyrazol-4-yl)-(2-fluorophenyl)methanone Chemical compound CCC1=NN(C)C(N)=C1C(=O)C1=CC=CC=C1F CGUWCWRVSCYBGD-UHFFFAOYSA-N 0.000 description 1
- PHVXRSPVNINUBA-UHFFFAOYSA-N (5-chloro-1,3-dimethylpyrazol-4-yl)-(2-fluorophenyl)methanone Chemical compound CC1=NN(C)C(Cl)=C1C(=O)C1=CC=CC=C1F PHVXRSPVNINUBA-UHFFFAOYSA-N 0.000 description 1
- PRDQWJXIVKFENE-UHFFFAOYSA-N (5-chloro-1-ethyl-3-methylpyrazol-4-yl)-(2-fluorophenyl)methanone Chemical compound ClC1=C(C(=NN1CC)C)C(C1=C(C=CC=C1)F)=O PRDQWJXIVKFENE-UHFFFAOYSA-N 0.000 description 1
- BOHSXKZUEZYFNF-UHFFFAOYSA-N (5-chloro-1-methyl-3-propan-2-ylpyrazol-4-yl)-(2-chlorophenyl)methanone Chemical compound ClC1=C(C(=NN1C)C(C)C)C(C1=C(C=CC=C1)Cl)=O BOHSXKZUEZYFNF-UHFFFAOYSA-N 0.000 description 1
- SLWKZOJXULTWJK-UHFFFAOYSA-N (5-chloro-3-ethyl-1-methylpyrazol-4-yl)-(2-chlorophenyl)methanone Chemical compound CCC1=NN(C)C(Cl)=C1C(=O)C1=CC=CC=C1Cl SLWKZOJXULTWJK-UHFFFAOYSA-N 0.000 description 1
- UNDXODJUWSUTGM-UHFFFAOYSA-N 1,2-dihydro-1,4-diazepin-7-one Chemical compound O=C1NCC=NC=C1 UNDXODJUWSUTGM-UHFFFAOYSA-N 0.000 description 1
- NODLZCJDRXTSJO-UHFFFAOYSA-N 1,3-dimethylpyrazole Chemical compound CC=1C=CN(C)N=1 NODLZCJDRXTSJO-UHFFFAOYSA-N 0.000 description 1
- JHTKOUJDEUQFOB-UHFFFAOYSA-N 1h-pyrazol-1-ium;chloride Chemical compound Cl.C=1C=NNC=1 JHTKOUJDEUQFOB-UHFFFAOYSA-N 0.000 description 1
- KKPKDMOLMFLFGF-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)-N-(1H-pyrazol-5-yl)acetamide Chemical compound C1(C=2C(C(N1CC(=O)NC1=NNC=C1)=O)=CC=CC2)=O KKPKDMOLMFLFGF-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- ULUACOYEFJQWKI-UHFFFAOYSA-N 2-bromo-N-[4-(2-chlorobenzoyl)-2-methyl-5-propan-2-ylpyrazol-3-yl]acetamide Chemical compound BrCC(=O)NC1=C(C(=NN1C)C(C)C)C(C1=C(C=CC=C1)Cl)=O ULUACOYEFJQWKI-UHFFFAOYSA-N 0.000 description 1
- WKZDWZUASJIPBC-UHFFFAOYSA-N 2-bromo-N-[4-(2-fluorophenyl)-2,5-dimethylpyrazol-3-yl]acetamide Chemical compound BrCC(=O)NC1=C(C(=NN1C)C)C1=C(C=CC=C1)F WKZDWZUASJIPBC-UHFFFAOYSA-N 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- RULINAPACRUGOF-UHFFFAOYSA-N 2-methyl-5-propyl-4h-pyrazol-3-one Chemical compound CCCC1=NN(C)C(=O)C1 RULINAPACRUGOF-UHFFFAOYSA-N 0.000 description 1
- RNIFYUPFVXLISB-UHFFFAOYSA-N 3,5-dimethyl-1H-pyrazole hydrobromide Chemical compound [Br-].CC=1N[NH+]=C(C=1)C RNIFYUPFVXLISB-UHFFFAOYSA-N 0.000 description 1
- CLPXHJRACWYTNN-UHFFFAOYSA-N 3-amino-1h-pyrazole-5-carbonitrile Chemical compound NC=1C=C(C#N)NN=1 CLPXHJRACWYTNN-UHFFFAOYSA-N 0.000 description 1
- IRPLFUJJHBGEAL-UHFFFAOYSA-N 3-amino-2-methyl-1h-pyrazol-5-one Chemical compound CN1NC(=O)C=C1N IRPLFUJJHBGEAL-UHFFFAOYSA-N 0.000 description 1
- GWZMWAZUCSGVLQ-UHFFFAOYSA-N 3-chloro-1-methylpyrazole Chemical compound CN1C=CC(Cl)=N1 GWZMWAZUCSGVLQ-UHFFFAOYSA-N 0.000 description 1
- ZAXITHHHFYZUGN-UHFFFAOYSA-N 3-ethyl-1-methylpyrazole Chemical compound CCC=1C=CN(C)N=1 ZAXITHHHFYZUGN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QZBGOTVBHYKUDS-UHFFFAOYSA-N 5-amino-1,2-dihydropyrazol-3-one Chemical compound NC1=CC(=O)NN1 QZBGOTVBHYKUDS-UHFFFAOYSA-N 0.000 description 1
- OBGZTDBPTVMFMT-UHFFFAOYSA-N 5-amino-3-ethyl-1-methylpyrazole-4-carbonitrile Chemical compound CCC1=NN(C)C(N)=C1C#N OBGZTDBPTVMFMT-UHFFFAOYSA-N 0.000 description 1
- ZLNJYINENJTGCF-UHFFFAOYSA-N 5-chloro-1-ethyl-3-methylpyrazole Chemical compound CCN1N=C(C)C=C1Cl ZLNJYINENJTGCF-UHFFFAOYSA-N 0.000 description 1
- XUXTVZZVQCDOKQ-UHFFFAOYSA-N 5-chloro-1-methyl-3-propan-2-ylpyrazole Chemical compound CC(C)C=1C=C(Cl)N(C)N=1 XUXTVZZVQCDOKQ-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- XZZMBFVRHGIIGW-UHFFFAOYSA-N 5-chloro-3-ethyl-1-methylpyrazole Chemical compound CCC=1C=C(Cl)N(C)N=1 XZZMBFVRHGIIGW-UHFFFAOYSA-N 0.000 description 1
- UIARRXNAPPSDFS-UHFFFAOYSA-N 5-ethyl-2-methyl-4h-pyrazol-3-one Chemical compound CCC1=NN(C)C(=O)C1 UIARRXNAPPSDFS-UHFFFAOYSA-N 0.000 description 1
- QBNRQCHCKIIYGV-UHFFFAOYSA-N 5-propyl-1h-pyrazole Chemical compound CCCC1=CC=NN1 QBNRQCHCKIIYGV-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- WINJFUOWMHKRHY-UHFFFAOYSA-N N-(4-benzoyl-2,5-dimethylpyrazol-3-yl)-2-bromoacetamide hydrobromide Chemical compound Br.C(C1=CC=CC=C1)(=O)C=1C(=NN(C1NC(CBr)=O)C)C WINJFUOWMHKRHY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WIRUZQNBHNAMAB-UHFFFAOYSA-N benzene;cyclohexane Chemical compound C1CCCCC1.C1=CC=CC=C1 WIRUZQNBHNAMAB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical class [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- DHZPZBFOJDXEHS-UHFFFAOYSA-N methyl hex-2-ynoate Chemical compound CCCC#CC(=O)OC DHZPZBFOJDXEHS-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- PUMCQAGLTAGULO-UHFFFAOYSA-N methyl pent-2-ynoate Chemical compound CCC#CC(=O)OC PUMCQAGLTAGULO-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
New pyrazoXo/3»4-≤7 D-*§J diazepin- -7(lH)-one compounds and methods for their production PARKE, BAVIS & COMPASY C: 32586 The present invention relates to new pyrazolodiazep none compounds that are useful as pharmacological agents and to methods for their production. More particularly, the invention relates to new pyrazolo[3 , -e] [1,^ ]diazepin-7(lH)-one compounds having the formula and to pharmaceutically-acceptable salts thereof; where is methyl or ethyl , R2 is an alkyl group having fewer than H carbon atoms or chlorine, is hydrogen or methyl, and Ar is phenyl, o-fluorophenyl , or o-chlorophenyl .
In accordance with the invention, pyrazolodiazepinone compounds having formula I above and salts thereof are produced by reacting a -aroyl-5-(2-phthalimidoacetamido)pyrazole compound having the formula A: II with hydrazine, where e^ch of ¾, 1*2> ¾3» and A* s as defined previously. The reaction is preferably carried out in an unreactive solvent medium. Solvents that may be used include lower alkanols, such as methanol, ethanol, and 2- propanol; ethers, such as dioxane, tetrahydrofuran , and diethylene glycol dimethyl ether; chlorinated hydrocarbons, such as dichloromethane , chloroform, and sym-tetrachloro- ethane; tertiary amides, such as N,N-dimethylformamide, N,N- dimethylacetamide, and N-methyl-2-pyrrolidinone; acetonitrile; and dimethylsulfoxide; as well as mixtures of these. Individually preferred solvents are ethanol and dichloromethane.
Neither the temperature nor the duration of the reaction is critical, and both may be varied over a wide range, the temperature from about 20 to about 15C°C. and the duration from one to 8 hours. A preferred temperature is one between ho and 8θ°C, and at such a temperature, the reaction is essentially complete after a period of about 3 to 10 hours. While equivalent quantities of reactants may be employed, best results are obtained when at least two moles of hydrazine are used per mole of the -aroyl-5-(2-phthalimidoacetamido)pyrazole reactant. During the course of the reaction, phthalhydrazide is formed as an insoluble secondary product and is best removed prior to isolation of the desired pyrazolodiazepinone product. The pyrazolodiazepinone product may be isolated directly in the free form or in the form of 9 salt, by appropriate adjustment of the pH as desired.
The 4-aroyl-5-(2-phthalimidoacetamido)pyrazole compounds required as starting materials in the foregoing process are prepared by reacting a 5_amino- -aroylpyrazole having the formula III with phthalimidoacetyl chloride in an unreactive solvent. The -amino -aroylpyrazoles of formula III are in turn prepared by a variety of methods. One such method for the preparation of the 5-amino- -aroy1-3-(lower alkyl)pyrazoles, for example, is the following .
A methyl alkynoate having the formula IV is reacted with methyl- or ethylhydrazine to give a 5-pyra-zolone having the formula V which is in turn reacted with phosphorus oxychloride to give a 5-chloropyrazole having the formula VI The 5-chloropyrazole intemediate is next reacted with an aroyl chloride having the formula 0 II Ar-C-Cl VII in the presence of aluminum chloride to give a 4-aroyl-5« chloropyrazole having the formula VIII which is finally reacted with an amine compound having the formula IX to give the desired 5-amino- -aroyl-3~( lower alkyl)pyrazole starting material having the formula X In formulas IV-X, the symbols R^, R3, and Ar have the same meaning as previously given and R^ represents an alkyl group having fewer than carbon atoms.
The 5-amino- -aroyl-3-chloropyrazole intermediates, that is, the compounds of formula III wherein R2 is chlorine, are prepared according to the following method. Ethyl cyano-acetate is reacted with methyl- or ethylhydrazine, and the 5-amino-3-hydroxypyrazole product, having the formula, XI is reacted with an aryl carboxylic acid having the formula Ar-COOH XII in polyphosphoric acid to give a K-aroyl-5~arylamido pyrazole having the formula XIII which is next reacted with phosphorus oxychloride to give a 4-aroyl-5«*arylamido-3-chloropyrazole having the formula XIV This intermediate then either is reacted directly with hydro-bromic acid in acetic acid to give a 5-amino- -aroyl-3-chloropyrazole having the formula XV or is first reacted with a methylating agent in the presence of a strong base, and the methylated product is reacted with hydrobromic acid to give a 4»aroyl-5-methylamino-3-chloro-pyrazole having the formula XVI In formulas XI-XVI, the symbols and Ar again have the aforementioned significance.
The foregoing and related procedures are described in detail hereinafter for the preparation of individual compounds Also in accordance with the invention, pyrazolodiazepin-one compounds having formula I above and salts thereof are produced by reacting a pyrazole compound having the formula XVII salt thereof with ammonia; where each of R^, R * R3, and Ar is as defined previously and Z represents bromine, chlorine, or iodine, preferably bromine, or an alkyl- or arylsulfonyl group, such as p_-toluenesulfonyl, benzenesulfonyl, and meth-anesulfonyl. The reaction is best carried out in an unreac-tive solvent medium. Suitable solvents include lower alkanols, such as methanol, ethanol, and 2-propanol; tertiary amides, such as Ν,Ν-dimethylacetamide and N-methyl-2-pyrrolidinone; ethers, such as dioxane, tetrahydrofura , and 1,2=dimethoxy-ethane; and halogenated hydrocarbons, such as dichloromethane , chloroform, and carbon tetrachloride; as well as mixtures of these. Excess liquid anhydrous ammonia can also be used as a solvent. A preferred solvent is a lower alkanol. The temperature of the reaction is not critical and may be varied from -70 to 100°C, with a temperature in the range of from about to about 80°C being preferred. At a temperature in the preferred range, the reaction is essentially complete after about 10-20 hours, although shorter or longer times may also be satisfactorily employed. For best results, a large excess of ammonia is used. The pyrazolodiazepinone product may be isolated directly in the free form or in the form of a salt, by appropriate adjustment of the pH as desired.
The pyrazole compounds used as starting materials in the foregoing process are prepared as follows. The compounds of formula XVII wherein Z is halogen are obtained by reacting a -amino- -aroylpyrazole having formula III above with a halo-acetyl halide compound having the formula 0 II X-CI^-C-Xj^ XVIII where X is bromine, chlorine, or iodine, preferably bromine, and ∑i is bromine or chlorine. The compounds of formula XVII wherein Z is an alkyl- or arylsulfonyl group are obtained by reacting a 5~aniino- -aroylpyrazole having formula III with a -(alkyl- or arylsulfonyloxy)acetyl chloride having the formula 0 II Z-CHg-C-Cl XIX where Z is as defined above.
Further in accordance with the invention, pyrazolo-diazepinone compounds having formula I above are produced by the cyclization of a 5-(2-aminoacetamido) - -aroylpyrazole com= pound having the formula XX where R^, Rg, R3, and Ar have the same meaning as given ear° lier. The cyclization occurs readily under neutral or alkaline conditions over a wide range of temperatures. Because cyclization is rapid even at room temperature, the 5-(2° aminoacetamido) = -aroylpyrazole is normally not isolated as such but is prepared in situ under conditions whereby cyclization occurs. In one method, a 4-aroyl-5-(2-azidoacetamido) pyrazole compound having the formula XXI is reacted with a reducing agent under neutral or alkaline conditions, whereupon the free base 5-(2-aminoacetamido) -4-aroylpyrazole is formed and undergoes cyclization. In formula XXI, each of R^, R * 3, and Ar is as defined previously. Any of a number of reducing agents can be employed in this reaction, including hydrazine in the presence of a palladium-on-charcoal catalyst, iron powder and water in the presence of a catalytic amount of hydrochloric acid or acetic acid, and hydrogen in the presence of Raney nickel. Various solvents can be used for the reaction, with the choice of a proper solvent being dependent upon the reducing agent employed. In general, a lower alkanol can satisfactorily be employed as solvent with any of the reducing agents mentioned above. The temperature and duration of the reaction likewise will depend somewhat upon the chosen reducing agent. With any of the above-mentioned agents, however, the reaction can be satisfactorily carried out at a temperature between about 20 and about 100°C. and at such a temperature, will be essentially complete after a period of from 30 minutes to 30 hours. Best results are obtained by employing a moderate to large excess of reducing agent. When the reducing agent is hydrogen in the presence of Raney nickel, the hydrogen is preferably supplied to the reaction mixture under a pressure of about 50 lbs. /in.2, and the hydrogenation is continued until no more hydrogen is taken up.
In another method for accomplishing the cyclization, a salt, such as the hydrochloride, of one of the compounds of formula XX is reacted with a sufficient amount of base to neutralize the salt, whereupon the free base 5-(2-aminoacet-amido) - -aroylpyrazole is liberated and undergoes cyclization. The reaction of the salt with base is best carried out in a solvent medium, which may be water or an aqueous lower alka-nol. Any of a number of bases may be used, including alkali metal carbonates and bicarbonates , alkali metal hydroxides, and alkaline earth metal hydroxides. The preferred base is an aqueous alkali metal hydroxide. The temperature is not critical, and the reaction can conveniently be carried out at room temperature, that is, without external heating or cooling. The duration of the reaction is likewise not crit- ical but is dependent to a certain extent on the amount of base employed. Rapid reaction and best results are obtained when the reaction is made strongly basic (pH 10-12) .
The 5~(2-aminoacetamido)~ -aroylpyrazole salts are conveniently prepared by reducing a 4=aroyl-5=(2=azidoacetamido) -pyrazole having formula XXI under acidic conditions, such as by reaction with stannous chloride in excess hydrochloric acid or with excess formic acid in the presence of palladium-on= charcoal. When prepared in this way, it is most convenient to react the salt obtained directly with a base as described above without isolation.
The -aroyl-5=(2-azidoacetamido)pyrazoles of formula XXI are prepared by reacting a k°aroyl~5~(2-haloacetamido)pyrazole having the formula XXII with sodium azide in an unreactive solvent medium, such as j -dimethylformamide, where each of R R^* R¾» Ar, and X has the same meaning as previously given.
Further yet in accordance with the invention, pyrazolo-diazepinone compounds having the formula XXIII are produced by reacting a 5-amino- -benzimidoylpyrazole compound having the formula XXIV with a haloacetyl halide compound having the formula in the presence of a base; where each of R, , R , Ar, X, and has Che aforementioned significance. The reaction is best carried out in a solvent medium. Suitable solvents include aromatic hydrocarbons, such as benzene and toluene; chlorinated hydrocarbons, such as dlchloromethane and chloroform; and ethers, such as dioxane, tetrahydrofuran, and diethylene glycol dimethyl ether; as well as mixtures of these« A preferred solvent is dlchloromethane. Suitable bases for use in the reaction are the alkali metal hydroxides, with an aqueous solution of sodium hydroxide being preferred. The reaction proceeds readily at a temperature in the range of from -10 to o°C. and at such a temperature, is essentially complete after about 2-5 hours. Equimolar quantities of reactants may be employed; for best results, however, a moderate to large excess of base should be used.
The 5-amino- -benzimidoylpyrazole starting materials are prepared by first reacting an ethoxyalkylidenemalononitrile having the formula C2H5-0-G=>C(C )2 XXV with methyl- or ethylhydrazine and then reacting the 5-amino- -cyanopyrazole intermediate obtained, having the formula, XXVI with an aryl organometallic compound having the formula Ar-M XXVII and hydrolyzlng the reaction product under mild, neutral conditions; where each of R^, R , and Ar is as defined earlier and M represents lithium or -MgBr.
Still further in accordance with the invention, pyrazolodiazeplnone compounds having the formula Ar XXVIII are produced by reacting a pyrazolodiazeplnone compound having the formula XXIX with a methylating agent in the presence of a base; where Rl» ½» an< Ar nave tne same meaning as previously given.
Examples of methylating agents that may be used are a methyl halide, especially methyl iodide, methyl sulfate, and a methyl hydrocarbon sulfonate, such as methyl methanesulfonate and methyl p_-toluenesulfonate. Bases that may be used include alkali metal hydrides, such as sodium hydride and lithium hydride, alkali metal amides, such as sodamide and potassium amide, and alkali metal alkoxides. Of these, sodium hydride is preferred. The reaction is best carried out in an unreac~ tive solvent medium, which may be a tertiary amide, such as N,N-dimethylformamide, N,N»dimethylacetamide, and -methyl-2= pyrrolidinone; an ether, such as diethyl ether, tetrahydro-furan, and dioxane; an aromatic hydrocarbon, such as benzene and toluene; dimethylsulfoxide; and mixtures of these. Pre~ ferred solvents are Ν,Ν-dimethylformamide and dimethylsulfox- ide. The temperature and duration of the reaction are not critical and may be varied widely, the temperature from 0 to 100°C. and the duration from one to about 48 hours. The reaction can conveniently be carried out at room temperature, that is, without external heating or cooling, and at that temperature is essentially complete after about hours but may optionally be continued for up to 16 hours to insure completeness. Equimolar quantities of reactants and base may be employed, although a slight excess of any one is not harmful. For optimum yields, it is desirable to use a slight excess of both the methyl ting agent and base.
The compounds of the invention can exist in the free form having formula I above or in the form of an acid-addition salt. Pharmaceutically-acceptable acid-addition salts are formed by reaction of the free pyrazolodlazeplnone compounds with any of a number of inorganic acids, including hydrochloric, hydro-bromlc, hydriodic, nitric, sulfuric, and phosphoric, and with certain strong organic acids, such as methanesulfonic, benzene-sulfonic, and p_-toluenesulfonic .
The free pyrazolodlazeplnone compounds of formula I where is hydrogen also form pharmaceutically-acceptable salts by reaction with a strong base. Suitable strong bases for this purpose include alkali metal hydroxides, such as sodium hydroxide, potassium hydroxide, and lithium hydroxide; alkali metal hydrides, such as sodium hydride; alkali metal alkox-ides; and alkaline earth metal hydroxides.
The free pyrazolodiazepinone compounds and their salts may differ somewhat in certain physical properties, such as solubility in polar solvents, but they are otherwise equivalent for purposes of the invention.
The compounds of the invention are new chemical compounds that are useful as pharmacological agents. As such, they exert a depressant effect upon the central nervous system that is shown by their ability to prevent the occurrence of convulsions in laboratory animals following the administration of pentamethylenetetrazole and also by their ability to overcome inhibited behavior in animals placed in an anxiety-producing situation.
The anticonvulsant activity of the compounds of the invention is measured in a standard test that is carried out essentially as described by Chen et al„, A.M.A. Archives of Neurology and Psychiatry« Vol. 66, pages 329-33 (1951), and Vol. 68, pages 98-505 (I952), and by Chen et al., Journal of Pharmacology and Experimental Therapeutics, Vol. l03, pages I -61 (1951). In this test, each of a group of 5 rats is given a measured oral dose of a test compound, dissolved in water or suspended with acacia, followed 30 minutes later by a subcutaneous dose of 93 mg./kg. of pentamethylenetetrazole„ This quantity of pentamethylenetetrazole quickly produces convulsions in 98-100$ of untreated control rats. The treated animals are then observed visually for 30 minutes following administration of pentamethylenetetrazole, and anticonvulsive activity is judged by noting the time of onset and severity of clonic convulsive seizures and the number of animals completely protected from convulsions. The activity of a test compound at each dosage level is rated as follows: +, protection of all 5 rats; 3+, protection of 3 or rats; 2+, protection of one or 2 rats; 1+, delay in onset; 0, no effect.
The results obtained for some representative compounds of the present invention when tested by the foregoing procedure are shown in the following table. The compounds in the table are identified by reference to formula I.
ANTICONVULSANT ACTIVITY Compound Dose, 2 R3 ½L mg./kg.
CH. 2 CH^ phenyl 125 4+ 63 4+ 32 4+ 16 4+ 8 4+ 4 0 fluoro125 4+ phenyl 63 4+ 32 4+ 16 4+ 8 4+ 4 4+ 2 4+ 1 0-1+ C2H5 CHg phenyl 125 4+ 63 4+ 32 4+ 16 4+ 8 4+ 4 4+ 2 0 8 4+ 4 4+ 2 2-3+ : 1 0 C2H5 H phenyl 125 4+ 63 . 4+ 32 4+ 16 4+ 8 4+ 0-1+ ♦Administered as the hydrochloride salt.
The anti-anxiety activity of the compounds of the invention is determined in a test that measures food consumption by rats that have been placed in an anxiety»producing situation. In this test, newly arrived Holtzman male albino rats are allowed to adjust to the laboratory environment for at least 3 days before testing. When tested, the animals are experimentally naive, are under no condition of dietary deprivation, and weigh about 230 grams. After adjustment to the normal laboratory environment, each of a group of 8 rats is given a measured dose of test compound, dissolved in water or suspended in 0.2% aqueous methocel, by oral intubation and is immediately placed in an individual metabolism cage. A 30-minute period is allowed for absorption of the test compound. Each animal is then given access to a milk preparation in a graduated and calibrated tube. The preparation consists of one part sweetened condensed milk and two parts water. The total milk intake of each animal after one and 2 hours is recorded and compared with that of a group of 8 untreated control animals. The animals are also observed for any gross behavioral signs and symptoms. Greater than normal ingestion of milk by the treated animals is regarded as an indication that the test compound, by acting upon the inhibitory brain systems, has suppressed the natural tendency of rodents to become immobilized in a novel, anxiety-producing situation, as represented in the test by the isolation of the metabolism cage. A given dose of test compound is considered active if it causes a mean amount of ingestion greater than 5„0 ml. per animal at the end of the first hour of the test. During this same period, the untreated controls normally consume between 2.0 and 4.0 ml. of milk.
The anti-anxiety activities of some representative compounds of the present invention, as determined by the foregoing procedure, are shown in the following table, where the compounds again are identified by reference to formula I. The table also shows the results obtained for diazepam and chlordiazepoxide, which are known to be clinically useful for the treatment of anxiety states. The demonstration of activity for diazepam and chlordiazepoxide indicates the validity of the test procedure for determining anti-anxiety activity.
ANTI-ANXIETY ACTIVITY Compound Dose, Milk Intake After Ar me. /ke . 1 Hour , ml.
^CH^ ^¾ ^¾ phenyl o 11.5 CH CH3 £-fluoro 20 6.8 phenyl 10 11.3 8.2 2.5 7.8 I.25 8.4 0.625 8.9 O.3I2 7.1 O.I56 6.4 O.078 4.6 CH^ C2H5 CH3 phenyl 40 4.3 .3 I2.5 11.1 2.5 4.5 I.25 4.9 ♦CHg CH3 CH3 o-chloro- 4o 9.5 phenyl 20 ■8.9 6.5 6.1 2.5 6.8 I.25 4.1 CH^ ¾Η H phenyl 4o • 10.7 8.8 ■7.8 6.3 2.5 6.8 1.25 3.8 Diazepam 4o . 10.7 12.1 7Λ 7.1 2. 8.0 Chlordiazepoxide 40 I0.7 11.4 8.1 4.7 ♦Administered as the hydrochloride salt The compounds of the invention are preferably adminis° tered orally, as indicated above, although parenteral administration can also be used. They can be combined with either a solid or liquid carrier or diluent and made available in varying amounts in such pharmaceutical forms as tablets , capsules, powders, and aqueous and non-aqueous suspensions and solutions.
The invention is illustrated by the following examples.
Example 1: A mixture consisting of 8.2 g„ of ~benzoyl-l,3"dimethyl~ 5-(N=methyl-2-phthalimidoacetamido)pyrazole, L? g. of anhydrous hydrazine, and 150 ml. of dichloromethane is stirred and heated under reflux for 5 hours. Upon cooling, the mixture is filtered to remove the precipitated unwanted by-product, phthalhydrazide, and the filtrate is evaporated under reduced pressure. The residue is mixed well with 25 ml. of 2 hydro-chloric acid, and the acidic mixture is filtered to remove the insoluble solids. The filtrate is then made basic with concentrated aqueous ammonia, and the solid 6,8~dihydro-l,3 >8~ trimethyl- -phenylpyrazolo[3 , -e] [1 , ]diazepin-7(1H) -one that precipitates is isolated, washed with water, and dried; m.p. 177-179°C, following crystallization from toluene.
The free base product obtained above (2.5 g.) is dissolved in 15 ml. of a saturated hydrogen chloride in 2»pro» panol solution, the resulting solution is diluted with ether until precipitation is complete, and the 6,8»dihydro-l,3»8~ trimethyl- -phenylpyrazolo[3 , -e] [1 , ]diazepin»7(1H) -one, dihydrochloride that precipitates is isolated and dried; m.p. 157-159°C Example 2: A mixture consisting of 12 g. of -benzoyl-l,3-dimethyl~ 5-(2-phthalimidoacetamido)pyrazole, 2 g. of anhydrous hydrazine, and 100 ml. of ethanol is stirred and heated under reflux for 8 hours and is then evaporated under reduced pressure. The residue is stirred with 50 ml. of N hydrochloric acid at 80-90°C. for 10 minutes, cooled, and filtered. The filtrate is then made basic with concentrated aqueous ammonia, and the basic mixture is chilled to give a solid precipitate of 6,8-dihydro-l,3-dimethyl- -phenylpyrazolof3, -e]f1, ]=» diazepin-7(lH)-one, which is isolated, dried, and crystallized from ethanol; m.p. 259-262°C.
Example : Utilizing the general procedure described in Examples 1 and 2 above, the following pyrazolodiazepinone compounds are obtained from the reactions indicated below; (a) From the reaction of 8.5 g„ of 4~(o-fluorobenzoyl) -l,3-dimethyl-5-(N-methyl-2-phthalimidoacetamido)pyrazole with 1.2 g. of anhydrous hydrazine in 150 ml. of dichloromethane , there is obtained -( -fluorophenyl)-6,8°dihydro-='l,3 ,8~tri~ methylpyrazolo[3, -e][l, ]diazepin-7(lH)-one; m.p. 173-175°C , following crystallization from toluene. The sulfate salt is prepared as follows. The foregoing product (1.4 g.) is dis=> solved in 40 ml. of 0.5 N sulfuric acid, and the solution is lyophilized to give a colorless residue of the desired salt, which may be crystallized from methanol-ether. (b) From the reaction of 16 g. of 4-(o-chlorobenzoyl) -3=ethyl-l-methyl-5-(2-phthalimidoacetamido)pyrazole with 1.8 g. of anhydrous hydrazine in 300 ml. of dichloromethane, there is obtained 4-( -chlorophenyl)-3-ethyl-6,8-dihydro-l-methyl-pyrazolo[3,4-e][l,4]diazepin-7(lH)-one; m.p. 258-261°C, following crystallization from toluene. (c) From the reaction of 15 g. of 4-( _-chlorobenzoyl) -l-methyl-5-(N-methyl-2-phthalimidoacetamido)-3-propylpyrazole with 1.8 g. of anhydrous hydrazine in 300 ml. of dichloro° methane, there is obtained 4-(o-chlorophenyl)-6,8-dihydro-ls8« dimethyl-3-propylpyrazolo[3 ,4-e] [1,4 ]diazepin-7(1H)-one . (d) From the reaction of 15 g. of l-ethyl-4-(o-fluoro-benzoyl) -3-methyl-5-(2-phthalimidoacetamido)pyrazole with 2.0 g. of anhydrous hydrazine in 300 ml. of dichloromethane, there is obtained l-ethyl-4-(£-fluorophenyl) -6,8°dihydro-3~ methylpyrazolo[3,4-e][l,4]diazepin-7(lH)-one; m.p. 250-25l°C„, following crystallization from toluene.
Example h t (a) A solution of lh g. of -benzoy 1 » 1 , 3"dimethy1 = 5 (N= methyl-2-bromoacetamido)pyrazole in 200 ml. of a $ anhydrous ammonia in methanol solution is kept overnight at 20-25°C. and is then evaporated under reduced pressure. The residue is dissolved in dichloromethane, and the solution is washed with dilute aqueous sodium bicarbonate and with water, dried, and evaporated under reduced pressure to give a solid residue of 6, 8-dihydro-l,3 , 8-trimethyl- -phenylpyrazolo[3,^-e][l, ] » diazepin-7(lH)-one; m.p. 177-179°C, following crystallization from toluene. (b) Utilizing the procedure described in (a) of this example, from the reaction of 15 g. of 5-(2-bromoacetamido) - -(o-chlorobenzoyl) -3-isopropyl-l-methylpyrazole with 200 ml. of 5% ammonia in methanol solution, there is obtained °(o-chlorophenyl) -6 , 8-dihydro-3-isopropyl- 1-methylpyrazolo [3 , -e]= [l,4]diazepin-7(lH)-one; m.p. 223-22 °C, following crystallization from toluene. (c) Utilizing the procedure described in (a) above, from the reaction of 10 g. of ^-benzoyl -5°(2-bromoacetamido) »3~ chloro-l-methylpyrazole with 200 ml. of 5$ ammonia in methanol solution, there is obtained 3-chloro~6 , 8-dihydro~l-methyl= = phenylpyrazolo[3, -e][l,4]diazepin-7(lH)-one; m.p. 245-247°C, following crystallization from toluene. (d) Utilizing the procedure of (a) above, from the reac-tion of 35 g. of 5-(2-bromoacetamido) -4-(o-fluorophenyl) -1 ,3-dimethylpyrazole with 20 g. of anhydrous ammonia in 200 ml. of methanol, there is obtained -(©-fluorophenyl) -6,8-dihydro-l,3-dimethylpyrazolo[3,4-e][l,4]diazepin-7(lH)-one; m.p. 235-237°C. , following several crystallizations from toluene. The monohydrobromide salt, m.p. 295°C. (with decomposition), is obtained by treating a solution of the free base product in acetic acid with hydrogen bromide, diluting the resulting mixture with acetone until precipitation of the salt is complete, and isolating and drying the solid obtained.
Example 5 * To a saturated solution of ammonia in 300 ml. of 2-pro-panol is added 19 g. of -benzoyl-5-(2-bromoacetamido)~l,3~ dimethylpyrazole hydrobromide, and the resulting mixture is stirred and heated under reflux for 5 hours while a steady slow stream of ammonia gas is passed through it. The reaction mixture is then evaporated under reduced pressure, the residue is treated with water, and the aqueous mixture is extracted with dichloromethane. The dichloromethane extract is dried and evaporated to give a solid residue of 6,8-dihydro 1 ,3-dimethyl- -phenylpyrazolo[3 , -e] [1 , ]diazepin-7(1H) -one; m.p. 259-262°C, following crystallization from 9 $ ethanol. Example 6: A solution of 12 g. of 5-(2-bromoacetamido) -4-(£-chloro-benzoyl)-l,3-dimethylpyrazole in 50 ml. of methanol is mixed with a solution of 25 g. of anhydrous ammonia in 220 ml. of methanol, and a stream of ammonia gas is passed through the resulting solution for 2 hours. It is then kept at 20-25°C. for 48 hours and evaporated to dryness. The residue is dissolved in dichloromethane, and the solution is washed with water and with saturated aqueous sodium chloride, dried, and evaporated under reduced pressure to give a solid residue of 4-(o-chlorophenyl) -6,8-dihydro-l,3-dimethylpyrazolo[3 , -e]-[l,4]diazepin-7(lH)-one; m.p. 237-24o°C, following crystallization from toluene.
Example 7: A mixture consisting of 22 g. of 4-benzoyl-5~(2-bromo-acetamido)-3-ethyl-l-methylpyrazole monohydrobromide, 75 ml„ of anhydrous liquid ammonia, and 100 ml. of dichloromethane is stirred and heated under reflux for 5 hours. The mixture is then concentrated under reduced pressure to remove the excess ammonia, and the concentrated dichloromethane solution is washed with water, dried, and evaporated under reduced pressure to give a solid residue of 3-ethyl-6, 8-dihydro-l-methyl- -phenylpyrazolo [ 3>^-e][l,^]diazepin- 7(1H) -one; m.p . 268-270°C, following crystallization from methanol., Example 8; To a suspension of 22 g. of 5-(2-bromoacetamldo) -3-ethyl- -(o-fluorobenzoyl) -1-methylpyrazole in 400 ml. of methanol at -30°C. is added 30 g. of liquid ammonia, and the resulting mixture is kept at 0-lO°C. for 16 hours and is then evaporated under reduced pressure. The residue obtained is mixed well with 300 ml. of dichloromethane, and the mixture is filtered to remove the insoluble solid. The filtrate is then evaporated under reduced pressure to give a solid residue of 3-ethyl- -(o-fluorophenyl) -6 , 8-dihydro-l-methyl-pyrazolo[3,^-e][l, ]diazepin-7(lH)-one; m.p. 253=255°C, following crystallization from acetone.
The hydrobromide salt is obtained by dissolving 1.0 g. of the above free base product in 3 ml. of 20$ hydrogen bromide in glacial acetic acid solution and then treating the solution with sufficient acetone to effect crystallization of the desired solid salt, which is isolated and dried.
The sodium salt is obtained as follows. 3"Ethyl-fluorophenyl) -6,8»dihydro-l-methylpyrazolo[3 ,4-e] [ 1 s ]-diazepin-7(lH) -one (2 .5 g.) is added to a solution of sodium methoxide, prepared by dissolving 0 .25 g« of sodium metal in 100 ml. of methanol, and the resulting mixture is stirred and heated at about 50°C. The solution obtained is then evaporated under reduced pressure, and the solid residue is dis° solved in 100 ml . of water . The aqueous solution is then subjected to lyophilization to give a solid residue of the desired salt.
Example 9 : To a solution of g. of 5-amino-4-(o°chlorobenzoyl)°l-ethyl-3-methylpyrazole in 400 ml. of ethyl acetate heated under reflux is added slowly 80 g. of bromoacetyl bromide, and the resulting mixture is stirred and heated under reflux for one hour and then evaporated under reduced pressure. The residue, which contains 5-(2=bromoacetamido) ~4~( ~chloro= benzoyl) -l-ethyl-3-methylpyrazole monohydrobromide, is dissolved in 600 ml. of methanol, and a stream of anhydrous ammonia gas is passed through the solution for 3 hours at room temperature. The solution is kept at 20-25°C. for 48 hours and is then evaporated under reduced pressure. The residue obtained is dissolved in dlchloromethane, and the solution is washed with aqueous sodium chloride, dried, and evaporated to give a solid residue of -(<-chlorophenyl) -1-ethy 1- 6,8-dihydro -3-methylpyrazolo [3 , -e][l,4 ]diazepin- 7( 1H) -one; m.p. 2 6-248°C, following crystallization from toluene. Example 10.
A mixture consisting of 8.8 g. of 4-benzoyl-3-chloro=l-methyl-5- [2-(£-toluenesulfonyloxy)acetamido]pyrazole, 50 ml. of 30$ aqueous ammonia, and 50 ml. of 2-propanol is stirred at 20-25°C. for 12 hours, then heated under reflux for 6 hours, and evaporated under reduced pressure. The residue is partitioned between dlchloromethane and 1 aqueous sodium hydroxide, and the dlchloromethane phase is separated, washed with water, dried, and evaporated to give a solid residue of 3-chloro-6 , 8-dihydro-l-methyl-4-phenylpyrazolo [3 ,4-e][l,4 ]~ diazepin-7(lH)-one; m.p. 245-247°C. , following crystallization from toluene.
Example 11.
To a solution of 16 g. of 4-benzoyl-l,3-dimethyl-5-(N-methyl-2-azidoacetamido)pyrazole in 150 ml. of ethanol is added 1.7 g. of anhydrous hydrazine and 1.0 g. of 5$ palladium-on-carbon, and the resulting mixture is heated under nitrogen at o°C. for 90 minutes. The catalyst is then removed by filtration, and the filtrate is evaporated under reduced pressure to give a solid residue of 6,8-dihydro-l , 3 ,8-trimethyl- -phenylpyrazolo[3, -e][l, ]diazepin-7(lH)-one; m.p. 177-179°C, following crystallization from toluene.
Example 12: To a solution of 9.0 g. of 5-(2=azidoacetamido) - -benzoyl-1,3-dimethylpyrazole in 90 ml. of ethanol and ho ml. of water is added 9.0 g. of reduced iron powder and 1.0 ml. of concentrated hydrochloric acid, and the resulting mixture is stirred and heated under reflux for one hour. It is then filtered, and the filtrate is evaporated under reduced pressure. The residue obtained is dissolved in chloroform, and the solution is washed with dilute aqueous sodium hydroxide and with water, dried, and evaporated under reduced pressure to give a solid residue of 6,8-dihydro-l,3-dimethyl- -phenylpyrazolo[3, =e]° [l, ]diazepin-7(lH)-one; m.p. 259-262 °C. , following crystallization from ethanol.
Example 1 : To a mixture of 18 g. of stannous chloride dihydrate and I50 ml. of 2 N hydrochloric acid at room temperature is added in portions 12 g. of -benzoyl-3-ethyl-l-methyl-5°(N-methyl»2~ azidoacetamido)pyrazole, and the resulting mixture is stirred at room temperature for 3 hours. Glacial acetic acid (25 ml.) and 10 g. more of stannous chloride dihydrate are then added, and the mixture is stirred at room temperature overnight. It is then filtered to remove a small amount of insoluble solid, and the filtrate is diluted with 150 ml. of water. The aqueous mixture is treated with excess hydrogen sulfide and filtered, and the filtrate is evaporated to dryness under reduced pressure. The solid residue obtained, which contains -benzoyl-3-ethyl-l-methyl-5-(N-methyl-2-aminoacetamido)pyrazole hydrochloride, is dissolved in 50 ml. of water, and the aqueous solution is made basic with excess concentrated aqueous ammonia. The basic mixture is extracted with dlchloromethane, and the dlchloromethane extract is dried and evaporated to give a solid residue of 3-ethyl-6,8-cihydro-l,8»dimethyl- -phenyl-> pyrazolo[3, -e][l, ]diazepin-7(lH)-one; m.p. 190-192°C, following crystallization from ether.
The methanesulfonate salt is obtained by treating a solution of 0.84 g. of the foregoing free base product in ml. of hot toluene with 0.3 g« of methanesulfonic acid and then adding sufficient dry ether to bring about the crystallization of the desired salt.
Example ΙΑ; To a stirred mixture consisting of 5 - 0 g. of 5°amino~ ~ benzimidoyl-l,3-dimethylpyrazole, 50 mL of 0.5 N aqueous sodium hydroxide, and 250 ml. of dichloromethane cooled to 5-8°C. is added dropwlse 5 »0 g. of bromoacetyl bromide, and the resulting mixture is stirred at 5-8°C. for 1 minutes. Stirring is then continued for 2 hours at 5°8°C. while 25 ml. of 1 aqueous sodium hydroxide is added in 5 ml. portions. The reaction mixture is then allowed to warm to room temperature, and the organic phase is separated, dried, and evaporated under reduced pressure to give a solid residue of 6 , 8» dihydro-1,3-dimethy 1 -k-phenyIpyrazolo[ 3 , -e] [ 1 , ]diazepin-7(lH)-one; m.p. 259-262 °C, following crystallization from toluene. The monohydrochloride salt, m.p. >300°C. , is obtained by treating a solution of free base in 2-propanol with hydrogen chloride, diluting the resulting mixture with ether until precipitation is complete, and isolating and drying the solid obtained.
Example 15; To a mixture consisting of .7 g. of 6, 8»dihydro-l,3~ dimethyl-h-phenylpyrazolo[ 3 , -e] [ 1 , 4 ]diazepin°7( 1H) -one , 1.0 g. of 0$ sodium hydride in mineral oil dispersio , and 50 ml. of Ν,Ν-dimeth lformamide at 20-25°C. is added 3.0 ml. of dimethyl sulfate, and the resulting mixture is kept at 20-25°C. for 16 hours. It is then diluted with an equal volume of water, and the aqueous mixture is extracted with di-chloromethane. The dichloromethane extract is washed with dilute aqueous sodium hydroxide and with water, dried, and evaporated under reduced pressure to give a solid residue of 6,8-dihydro-l,3 ,8-trimethyl-4-phenylpyrazolo[3,4-e][l,4]-diazepin-7(lH)-one; m,p. 177-l79°C, following crystallization from toluene.
Example 16t To a suspension of 4.2 g. of 4-(o-fluorophenyl) -6,8-dihydro-1 ,3-dimethylpyrazolo[3 ,4-e] [1,4 ]diazepin-7(1H) -one monohydrobromide in 50 ml. of N,N-dimethylformamide under nitrogen is added in portions 1.5 g. of 50$ sodium hydride in mineral oil dispersion. The resulting mixture is stirred at room temperature for 30 minutes, 4.0 ml. of dimethyl sulfate is added, and the reaction mixture is kept at room temperature for 16 hours and then evaporated under reduced pressure. The residue obtained is extracted with dichloromethane, and the dichloromethane extract is washed with water, dried, and evaporated under reduced pressure. The residue is dis- solved in a small amount of acetone, and the acetone solution is poured onto a chromatography column prepared from activated magnesium silicate (Florisil) . The column is elute.d with acetone, and the eluates obtained are combined and evaporated to give a solid residue of 4-(o-fluorophenyl) »6,8-dihydro-1,3 ,8°trimethylpyrazolo[3 ,4-e] [1, ]diazepin-7( 1H) -one; m.p . 173~l75°C, following crystallization from ether.
Example 17; To a suspension of 5.3 g. of 4-(t)-chlorophenyl) -6,8= dihydro-1 ,3-dimethylpyrazolo[3 ,4-e] [1,4 ]diazepin°7(lH) -one in 60 ml. of N,N-dimethylformamide is added, in portions at 5°C., 1.0 g. of 50 sodium hydride in mineral oil dispersion. To the resulting solution is then added dropwise 5.0 go of methyl iodide, and the resulting mixture is stirred for one hour at room temperature and is then evaporated under reduced pressure. The residue obtained is dissolved in dichloromethane, and the solution is washed with aqueous sodium chloride, dried, and evaporated under reduced pressure to give a solid residue of -(o-chlorophenyl) -6, 8-dihydro-l,3 ,8=t imethylpyrazolo[3 ,4=e]-[1,4 ]diaze in-7(lH) -one. The monohydrochloride salt, m.p. 260°C. (with decomposition), is obtained by treating a solution of the free base in 2-propanol with hydrogen chloride, diluting the resulting mixture with ethyl acetate until precipitation is complete, and isolating and drying the solid obtained.
Example 18; To a solution of 6.7 g. of 3-ethyl-6,8-dihydro°l«*methyl-4-phenylpyrazolo[3, -e][l, ]diazepin-7(lH) -one in 30 ml. of dimethyl sulfoxide at room temperature under nitrogen is added in portions 1.5 g. of 0$ sodium hydride in mineral oil dispersion. The mixture is stirred for 30 minutes, 5.0 g. of methyl iodide is added dropwise, and stirring is then continued for 2 hours at room temperature. The mixture is diluted with 200 ml. of ether, and the ethereal solution is washed several times with water, with 1 aqueous sodium hydroxide, and with water again, dried, and concentrated to a small volume from which upon cooling there is obtained a crystalline precipitate of 3-ethyl-6,8-dihydro-l,8-dimethyl- -phenyl-pyrazolo[3,4-e][l,4]diazepin-7(lH)-one; m.p. 191-193°C Example Ig: Utilizing the procedure described in Example 17 above, the following pyrazolodiazepinone compounds are obtained from the reactions indicated below: (a) From the reaction of 3.0 go of 4=(o-chlorophenyl) -1- ethyl-6,8-dihydro-3-methylpyrazolo[3 ,4-e] [1 ,4 ]diazepin~7( IH) -one with 0.5 g. of 55$ sodium hydride in mineral oil dispersion in 20 ml. of dimethyl sulfoxide and then with 2.0 g. of methyl iodide in 20 ml. of ether, there is obtained 4-(£-chlorophenyl) -1-ethyl-6, 8-dihydro-3 »8-dimethylpyrazolo[3 ¾ -e]-= [1, ]diazepin-7(lH) -one, obtained as a glassy semisolid. (b) From the reaction of 3.5 g. of ~(o-chlorophenyl) -3-ethyl-6, 8-dihydro-l-methylpyrazolo[3 ,4°e] [1 ,4 Jdiazepin°7(IH) » one with 0.6 g. of 5$ sodium hydride in mineral oil dispersion in 25 ml. of dimethyl sulfoxide and then with 2.0 g. of methyl iodide, there is obtained 4-(o-chlorophenyl) -3-ethyl-6,8-dihydro-l, 8-dimethylpyrazolo[ ,3-e] [1,4 ]diazepin-7(lH) -one; m.p. II5.5-ll7°C. , following crystallization from ether. Example 20; To a stirred mixture consisting of 0.7 g. of 0$ sodium hydride in mineral oil dispersion^ 2.0 ml. of methyl iodide, and 20 ml. of N, -dimethyIformamide is added in portions 3.7 g. of 3-ethyl-4-(o-fluorophenyl) =6,8-dihydro=l-methyl-pyrazolo[3,4-e][l,4]diazepin-7(lH)-one, and the resulting mixture is stirred at room temperature for one hour. It is then diluted with I50 ml. of dichloromethane, and the mixture obtained is washed several times with water. The dichloro- i methane solution is then dried and evaporated under reduced pressure. The oily residue is dissolved in 30 mL of ethyl acetate, and the solution is extracted with 75 ml. of 2 N hydrochloric acid. The acidic extract is made basic with concentrated aqueous ammonia, and the basic mixture is extracted with chloroform„ The chloroform extract is then dried and evaporated under reduced pressure to give a solid residue of 3-ethyl-4-(o-fluorophenyl) -6,8-dihydro-l,8-di-methylpyrazolo[3 ,4-e][l,4]diazepin-7(lH)-one; m.p. 175~177°C, following crystallization from ether.
Starting Materials The various starting materials employed in the foregoing Examples and intermediates required for their preparation are obtained by the methods described in the following. A. 5-Pyrazolones. ( 1) 3~Ethyl=l-methyl-5-pyrazolone. To an ice cold solution of 10 g. of methylhydrazine in 200 ml. of methanol is added dropwise 22 .5 g« of methyl 2-pentynoate. The reaction mixture is stirred at 0-10°C. for 4 hours and at 20-25°C. for 16 hours and is then evaporated under reduced pressure to give 3~ethyl-l-methyl-5-pyrazolone; m.p. 101-103°C, following crystallization from benzene-petroleum ether. (2 ) 1-Methyl "3"Pro yl -5 -pyrazolone , m„p„ 109~1H°C« s following crystallization from benzene-petroleum ether; obtained by the method of (1) above from the reaction of 30 gu of methylhydrazine with 126 g. of methyl -hexynoate., (3 ) 3-Isopropyl-l-methy1-5-pyrazolone, m.p. ll3~il5°C., following crystallization from benzene-petroleum ether; ob° tained by the method of (1) above from the reaction of 50 g„ of methylhydrazine with 126 g. of methyl ¼ -methyl- 2 -pentynoate„ B . 5-Chloropyrazoles . (1) 5-Chloro-l-ethyl-3-methylpyrazole. A mixture of 26 g. of l-ethyl-3-methyl-5-pyrazolone (for the preparation of this compound, see Helv. Chim. Acta. „ Vol. 32 , page 984 , I9 9) and 6^5 g. of phosphorus oxychloride is stirred and heated under reflux for 16 hours and is then poured cautiously into a mixture of 200 ml. of concentrated aqueous ammonia, 200 g. of ice, and 200 ml. of ether . After about 30 minutes, the organic phase is separated, and the aqueous phase is extracted 3 times with ether. The separated organic phase and the ether extracts are combined, dried, and evaporated to give an oily residue of 5=chloro-l»ethyl-3-methylpyrazole; b.p. 55-57°C/lO mm. Hg. (2 ) 5-Chloro-3-ethyl-l-methylpyrazole, b.p. 82-83 °C0 /28 mm. Hg; obtained by the method of ( 1) above from the reaction ■ί of 126 g. of 3-ethyl- 1-methyl -5-pyrazolone with 320 g „ of phosphorus oxychloride. (3 ) 5-Chloro=-l-methyl-3-propylpyrazoles b.p. 78-7 °C-/lO mm. Hg; obtained by the method of ( 1) above from the reaction of I25 g. of 1-methyl -3-propyl -5-pyrazolone with 310 g. of phosphorus oxychloride. (4) 5-Chloro-3-isopropyl-l-methylpyrazole, b r . 72° 7 °C. /10 mm. Hg; obtained by the method of ( 1) above from the reaction of 123 g. of 3-isopropyl-l-methyl-5~pyrazolone with 320 g. of phosphorus oxychloride.
C. -Aroyl-5-chloropyrazoles . (1) -Benzoyl-5-chloro-l,3-dimethylpyrazole. To a suspension of o g. of anhydrous aluminum chloride in 200 ml, of sym-tetrachloroethane is slowly added first 39 g. of 5°chloro-1,3-dimethylpyrazole (for the preparation of this compound, see J. prakt. Chem., Vol. 110 , page 153» 1925; Chem, Abstro, Vol. 19 , page 2952 , 1925) , then 6 g. of benzoyl chloride. The resulting mixture is stirred and heated under reflux for 18 hours, cooled, and poured into a mixture of ice water and concentrated hydrochloric acid. The organic phase is separated, washed with 200 ml. of 4 N aqueous sodium hydroxide, dried, and evaporated to give an oily residue of 4-benzoyl~5" chloro-l,3-dimethylpyrazole; b.p„ 128°130°C. /O .2 mm. Hg. (2) 5"Chioro - -(£-chlorobenzoyl) -1 , 3"dimethylpyrazole„ A mixture consisting of 38 g. of 5-chloro-l,3-dimethylpyrazole 53 g. of o-chlorobenzoyl chloride, 4o g. of anhydrous aluminum chloride, and 250 ml. of synt-tetrachloroethane is stirred and heated under reflux for 18 hours, Cooled, and poured into ice water. The organic phase is separated, stirred with 300 ml. of dilute aqueous sodium hydroxide for one hour, separated again, washed with water, dried, and evaporated to give 5= chloro- -(o-chlorobenzoyl)-l,3-dimethylpyrazole; m.p. 70-72°C. following crystallization from carbon tetrachloride-petroleum ether. (3) 5-Chloro-4-(o-fluorobenzoyl) -1 ,3-dimethylpyrazole, m.p. 70-72°C.; obtained by the general method described in ( 1) and (2 ) above from the reaction of 64 g. of 5~chloro~l,3~ dimethylpyrazole with 90 g. of o-fluorobenzoy 1 chloride in the presence of 75 g. of anhydrous aluminum chloride in 300 ml. of sym-tetrachloroethane. (4) 5-Chloro-4-(o-chlorobenzoyl) -1-ethyl ~3"methylpyra~ zole, m.p. 62-64°C, following crystallization from hexane; obtained by the general method of ( 1) and (2 ) above from the reaction of 43 .2 g. of 5-chloro-l~ethyl=3-methylpyrazole with 53 g. of o-chlorobenzoyl chloride and 4o g. of anhydrous aluminum chloride in 200 ml. of sym-tetrachloroethane.
J* (5) 5-Chloro-4- (o-chlorobenzoyl) -3-ethyl-l-methylpyra= zole, m.p. 77-79°C.; obtained from the reaction of 72 g. of -chloro-3-ethyl-l-methylpyrazole with 88 g. of o-chlorobenzoyl chloride and 70 g. of anhydrous aluminum chloride in 200 ml. of sym-tetrachloroethane. (6) 5-Chloro-4-(o-chlorobenzoyl) -l-methyl-3-propyl- pyrazole, b.p. 180-183 °C./0. mm. Hg; obtained from the reaction of 8o g. of 5-chioro-l-methyl-3-propylpyrazole with 90 g. of o-chlorobenzoyl chloride and 70 g. of anhydrous aluminum chloride in 200 ml. of sym-tetrachloroethane. (7) 5-Chloro- -(o-chlorobenzoyl) -3-isopropyl-l-methyl- pyrazole, b.p. l48-l50°C./0.2 mm. Hg; obtained from 80 g. of -chloro-3-isopropyl-l-m¾thylpyrazole, 90 g. of o-chlorobenzoyl chloride, and 7C g. of anhydrous aluminum chloride in 200 ml. of sym-tetrachloroethane. (8) 5-Chloro-l-etbyl- -(o-fluorobenzoyl) -3-methylpyra- zole, b.p. 128-130°C./0.1 mm. Hg; obtained from 2 g. of 5" chloro-l-ethyl-3-methyl rrazole, 80 g. of o-fluorobenzoyl chloride, and 75 g. of anhydrous aluminum chloride in 300 ml. of sym-tetrachloroethane.
D. 5-Amino-4-aroylpyrazples. (1) 4-Benzoyl-l,3-dlmethyl-5-(methylamino)pyrazole. A mixture consisting of 50 g. of ~benzoyl-5'"chloro-i^"di-methylpyrazole and 120 ml. of k0 aqueous methylamine is heated in a closed pressure vessel at 155~160°C. for 5 hours and is then evaporated under reduced pressure. The residue is dissolved in dichloromethane, and the solution is mixed well with 1 N aqueous sodium hydroxide. The organic phase is separated, washed with water, dried, and evaporated to give -benzoyl -1 ,3-dimethyl -5-(methylamino)pyrazole; m„p. 77-79°C., following crystallization from cyclohexane. (2) 5-Amino- -benzoyl-l,3-dimethylpyrazole. To a solu-tion of phenyl lithium, prepared from 70 g. of bromobenzene and 5.6 g. of lithium in OO ml. of ether, is added in porions 25 g. of 5-amino-½-cyano-l,3-dimethylpyrazole, (For the preparation of this compound, see J. Org. Chem. ¾ Vol. 2ls page I250 , I956. ) The resulting mixture is stirred and heated under reflux for 18 hours, cooled, and treated with 150 ml. of saturated aqueous ammonium chloride. The organic phase is separated and extracted with boo ml. of 1 N hydrochloric acid. To the acidic aqueous extract is added 20 ml. of concentrated hydrochloric acid, and the mixture obtained is heated at 8c-90°C. for 10 minutes, cooled, and made strongly basic with 50$ aqueous sodium hydroxide. The basic mixture is extracted with chloroform, and the chloroform extract is washed with water, dried, and evaporated to give 5-amino« -benzoyl~ls3~ dimethylpyrazole; m.p. Ik7-l50°C, following crystallization from benzene. (3) 5-Amino- -(o-chlorobenzoyl) -1,3-dimethylpyrazole. A mixture of kO g. of 5-chloro-4-(o_»chlorobenzoyl) -l,3~di-methylpyrazole and 120 ml. of 30$ aqueous ammonia is heated in a closed pressure vessel at 155-160°C. for 5 hours, then cooled, and evaporated under reduced pressure. The residue is mixed well with a mixture of dichloromethane and dilute aqueous sodium hydroxide, and the dichloromethane phase is separated, washed with water, dried, and evaporated to give a solid residue of 5-amino- -(o-chlorobenzoyl)-l,3-dimethyl-> pyrazole; m.p. 102-103°C., following crystallization from benzene-cyclohexane. ( ) 5-Amino- -(o-fluorobenzoyl) -1,3-dimethylpyrazole,, m.p. 108-l09°C, following crystallization from ethyl acetate petroleum ether; obtained by the procedure of (3) above from the reaction of 76 g. of 5-chloro- -(o~fluorobenzoyl)~l,3° dimethylpyrazole with 2ho ml. of 28$ aqueous ammonia. (5) 5-Amino- -benzoyl-3~ethyl-l°methylpyrazole; obtained as an oil suitable for use without further purifica- cion by the method of (2) above from the reaction of 15 g. of 5-amino-4-cyano-3-ethyl-l-methylpyrazole (for the preparation of this compound, see J. Med. Chem.. Vol. 11, page 79, 1968) with a solution of phenyl lithium, prepared from 70 g. of bromobenzene and 5.6 g. of lithium in 300 ml. of ether. (6) 5-Amino-4-(o-chlorobenzoyl) -l-ethyl-3-methylpyra-zo e; obtained as an oil suitable for use without further purification by the method of (3) above from the reaction of 57 g. of 5»chloro- -(o-chlorobenzoyl)-l-ethyl-3-methyl-pyrazole with I80 ml. of 2¾£ aqueous ammonia. (7) 5-Amino- -(o-chlorobenzoyl) -3-ethyl-l-methylpyrazole, m.p. 118-121°C; obtained by the method of (3) above from the reaction of 60 g. of 5-chloro- -(o-chlorobenzoyl) -3-ethyl-l-methylpyrazole with I80 ml. of 28$ aqueous axranonia. (8) -(o-Chlorobenzoyl) -1-methyl-5-(methylamino) - -propylpyrazole. A stream of methylamine gas is continuously bubbled through a solution of 60 g. of 5-chloro- -(o-chloro-benzoyl)-l-methyl-3-propylpyrazole in 100 ml. of dimethyl sulfoxide for 3 hours at 150-160°C. The resulting mixture is then cooled and diluted with an equal volume of dilute aqueous sodium hydroxide, and the basic mixture is extracted with ether. The ether extract is dried and evaporated to give an oily residue of 4-(oi-chlorobenzoyl)=l°methyl~5'= (methylamino)-3-propylpyrazole; b.p. 150 1 2°C. /0.2 mm. Hg„ (9) 5-Amino- -(p_-chlorobenzoyl) -3-isopropyl-l-methyl-pyrazole, b.p. 163-165°C. /0.15 mm. Hg; obtained by the method of (3) above from the reaction of 50 g. of 5°chloro-4~(£~ chlorobenzoyl)-3-isopropyl-l°methylpyrazole with 1 0 ml. of 2¾6 aqueous ammonia. (10) 5-Amino-l-ethyl-4-(o-fluorobenzoyl) -3-methyl° pyrazole; obtained as an oil suitable for use without further purification by the method of (3) above from the reaction of 80 g. of 5-chloro-l-ethyl-4-(o-fluorobenzoyl) -3-methylpyrazole with 240 ml. of 28$ aqueous ammonia. (11) 4-(o-Fluorobenzoyl)-l,3-dimethyl-5-(methylamino) -pyrazole.
To a cooled and stirred suspension of 27 g. of anhydrous aluminum chloride in 200 ml. of sym-tetrachloro-ethane is added first 31 g. of o-fluorobenzoyl chloride and then 11 g. of 5~a ino-l,3 dimethylpyrazole (for the prepara* tion of this compound, see J. Am. Chem. Soc. , Vol. 81 , page 2461, I959), and the resulting mixture is stirred and heated under reflux for 16 hours. Upon cooling, it is mixed with an equal volume of cold dilute hydrochloric acid, and the organic phase is separated and stirred well with 100 ml.« of saturated aqueous sodium bicarbonate. The organic phase is then separated again, dried, and evaporated to give a solid residue of 5-(o-fluorobenzamido) o-fluor©benzoyl ) »l,3»di~ methylpyrazole; m.p. 1 3-145°C, following crystallization from ethanol.
To a suspension of 3.0 g. of 50$ sodium hydride in mineral oil dispersion in 100 ml. of N,N-dimethylformamide at 10°C. is added in portions 18 g. of 5-(o-fluorobenzamido) - -(o-£luorobenzoyl)-l,3-dimethylpyrazole. The resulting solution is stirred for 30 minutes at 10°C, lk g. of methyl iodide is added, and the mixture obtained is stirred at 20-25°C. for 5 hours and then evaporated under reduced pressure., The residue is dissolved in dichloromethane, and the solution obtained is washed with water, dried, and evaporated to give a solid residue of -(o-fluorobenzoyl) -l,3-dimethyl-5-(N-methyl-io-fluorobenzamido)pyrazole; m.p. 115»118°C., following crystallization from ethyl acetate-petroleum ether, A mixture of 37 g. of the foregoing product and 200 ml. of 8$ hydrobromic acid is stirred and heated under reflux for 16 hours and then evaporated under reduced ressure. The residue is thoroughly mixed with a mixture of chloroform and 3 N aqueous sodium hydroxide, and the organic phase is separated, washed with saturated aqueous sodium bicarbonate, dried, and evaporated to give -(o_-fluorobenzoyl) -l,3-dimethyl-5-(methylamino)pyrazole, suitable for use without further purification. ( 12 ) 5-Amino- -benzoyl-3-chloro-l-methylpyrazole.
A mixture consisting of 22.6 g. of 5-amino-3-hydroxy-1-methylpyrazole (for the preparation of this compound, see J. Am. Chem. Soc.. Vol. 71, page 986 , 19^9) , ^8 g. of benzoic acid, and 400 g. of polyphosphoric acid is stirred and heated at 120-130°C. for 2 hours, cooled, and poured with stirring into I.5 liters of ice water. The solid 5-benzamido- -benzoyl-3-hydroxy-l-methylpyrazole that precipitates is isolated, washed with water, and dried; m.p. 198-200°C, following crystallization from 95$ ethanol.
The foregoing product (32 g.) is added in portions at room temperature to 75 ml. of phosphorus oxychloride, and the resulting mixture is stirred under reflux for 16 hours , cooled, and poured with stirring onto 600 g. of crushed ice. The solid 5-benzamido- -benzoyl-3-chloro-l°methylpyrazole that precipitates is isolated, washed with water, and dried; m.p. 193-195°C, following crystallization from chloroform-petroleum ether.
A mixture consisting of 16 g. of the foregoing prod° uct, 120 ml. of glacial acetic acid, and 60 ml. of 8$ hydro-bromic acid is stirred and heated under reflux for 3 hours and then evaporated under reduced pressure. The residue obtained is dissolved in chloroform, and the chloroform solution is stirred with a large excess of aqueous sodium bicarbonate.
The organic phase is separated, dried, and evaporated to give a solid residue of 5-amino- -benzoyl-3-chloro-l-methylpyrazole; m.p. 160-162°C, following crystallization from chloroform-petroleum ether. (13) 5-Amino-3-ethyl- -(o-fluorobenzoyl) -1-methylpyrazole , m.p. 103-1059C, following crystallization from ethyl acetate-petroleum ether; obtained by the general method described in ( 11) above, but without the methylation step, by first reacting 25 g. of 5-amino-3~ethyl-1-methylpyrazole (see British Patent 863 ,060 , March 15, 1961) with 75 g. of o-fluorobenzoyl chloride and 65 g. of aluminum chloride in 275 ml. of s m-tetrachloro= ethane and then reacting the 3-ethyl=5-(o-fluorobenzamido) ~k-(o-fluorobenzoyl) -1-methylpyrazole intermediate product obtained (36 g.) with I50 ml. of 8$ hydrobromic acid in 75 ml. of glacial acetic acid.
E. 4-Aroyl-5- (2-phthalimidoacetamido)pyrazoles. (1) -Benzoyl-l,3-dlmethyl-5-(N<-methyl-2-phthalimido» acetamido)pyrazole. To a solution of 11 g. of -benzoyl-1 ,3" dimethyl-5~(raethylamino)pyrazole in 100 ml „ of ethyl acetate, stirred and heated under reflux, is added dropwise a solution of 11 g. of phthalimidoacetyl chloride in 50 ml. of ethyl acetate, and the resulting mixture is stirred and heated under reflux for an additional hour and is then evaporated under reduced pressure. The residue obtained is dissolved in 100 ml. of chloroform, and the chloroform solution is washed succes~ sively with 1 hydrochloric acid, saturated aqueous sodium bicarbonate, and water, dried, and evaporated to give a solid residue of -benzoyl- 1 , 3-dimethyl -5-(N»methyl°2-phthalimido-acetamido)pyrazole; m.p. 176-17 °C, following crystallization from ethyl acetate-petroleum ether. (2) 4-Benzoyl-l,3-dimethyl-5-(2-phthalimidoacetamido) ~ pyrazole, m.p. 191-193°C, following crystallization from ether; obtained by a method analogous to that described in (1) above from the reaction of 11 g. of 5-amino- -benzoyl-1 ,3-dimethylpyrazole with 11 g. of phthalimidoacetyl chloride in 300 ml. of ethyl acetate. (3) 4-(o-Fluorobenzoyl)-ls3°dimethyl-5=(N-=»methyl-2- phthalimidoacetamido)pyrazoles m.p. 2l8="220°C.s following crystallization from 95$ ethanol; obtained by the procedure of (1) above from the reaction of 5.0 g. of 4»(o°fluoroben° zoyl) -l,3-dimethyl-5-(methylamino)pyrazole with 4.8 g. of phthalimidoacetyl chloride in 95 ml. of ethyl acetate. (4) 4-(o-Chlorobenzoyl) ~3°ethyl-l-methyl-5-(2~phthal-imidoacetamido)pyrazole, m.p. 261-263°C, following crystallization from toluene; obtained by a procedure analogous to that described in (1) above from the reaction of 13.2 g. of 5-amino-4-(o-chlorobenzoyl)=3-ethyl-l-methylpyrazole with 11 g. of phthalimidoacetyl chloride in 200 ml. of ethyl acetate. (5) -(o-Chlorobenzoyl) -1-methyl-5 (N-methyl-2-phthal-imidoacetamido)-3-propylpyrazole; obtained by a method analogous to that described in (1) above from the reaction of 13 ·5 g. of 4-(o-chlorobenzoyl) °l-methyl-5~(methylamino) ~3~ propylpyrazole with 11 g. of phthalimidoacetyl chloride in ethyl acetate. (6) l-Ethyl-4-(o»fluorobenzoyl) =3°methyl-5-(2-phthal~ imidoacetamido)pyrazole; obtained by the procedure of (1) above from the reaction of 12.2 g. of 5°amino l-ethyl-4~(o-fluorobenzoyl) -3-methylpyrazole with 11 g. of phthalimido° acetyl chloride in ethyl acetate.
F. ~Aroyl~5~(2~bromoacetamido)pyrazoles and Salts Thereof, (1) -Benzoyl-l ,3-dimethyl~5-(N"methyl~2='brOnioacetamido) -pyrazole. To a solution of 11.5 g. of -benzoyl 1 ,3"dimethyl-5-(methylamino)pyrazole in 75 ml. of ethyl acetate, stirred and heated under reflux, is added dropwise 10 go of bromo-acetyl bromide, and the resulting mixture is stirred and heated under reflux for one hour and is then chilled. The solid 4-benzoyl-l,3-dimethyl-5-(N-methyl-2-bromoacetamido) -pyrazole that precipitates is isolated and dried; m.p. 122- 124 °C, following crystallization from 2-propanol. (2) 4-Benzoyl-5-(2-bromoacetamido) -1 ,3-dimethylpyrazole hydrobromide. To a solution of 13 g. of 5=amino-4-benzoyl-1,3-dimethylpyrazole in 250 ml. of ethyl acetate, stirred and heated under reflux, is added dropwise 2 g. of bromoacetyl bromide, and the resulting mixture is stirred and heated under reflux for an additional hour and is then chilled. The solid precipitate of -benzoyl-5=(2-bromoacetamido) -1 ,3-dimethylpyrazole hydrobromide is isolated and crystallized from ethanol-ether; m.p. 181-183°C (3) 5-(2-Bromoacetamido) -4-(o-chlorobenzoyl) -1 ,3-di= methylpyrazole, m.p. 153-155°C, following crystallization from 2-propanol-ether; obtained by the general method of (1) and (2) above from the reaction of 16 g„ of 5-amino-4~(o~ chlorobenzoyl) ~1,3-dimethylpyrazole with 26 g. of bromoacetyl bromide in 200 ml. of ethyl acetate. (4) 5«(2- romoacetamido) - -(o-fluorophenyl) =193-ά±·= methylpyrazole, m.p. 190»192°C, following crystallization from 2=propanol; obtained by the general method described in (1) and (2) above from the reaction of 23 g» of 5~amino»4~(o~ fluorophenyl) -1,3-dimethylpyrazole with 21 g. of bromoacetyl bromide in 150 ml. of ethyl acetate. (5) -Benzoyl-5-(2-bromoacetamido) -3-ethyl-l-methyl-pyrazole hydrobromide, m.p. 189-191°C, following crystallization from 2-propanol-ether; obtained by the general method of (1) and (2) above from 11.5 g. of 5-amino-4-benzoyl-3° ethyl-l-methylpyrazole and 20 g. of bromoacetyl bromide„ (6) 5-(2-Bromoacetamido)°4-(£-chlorobenzoyl)-3-iso-propyl-1-methylpyrazole; obtained by the method of (1) above from I3.9 g. of 5-amino-4-(o-chlorobenzoyl) -3=isopropyl-l-methylpyrazole and 10 g. of bromoacetyl bromide. (7) 4-Benzoyl-5-(2-bromoacetamido) -3°chloropyrazoles m.p. 155-158°C; obtained by the method of (1) above from 7.6 g. of 5~an.ino-4-benzoyl~3°chloro~l methylpyrazole and 12 g. of bromoacetyl bromide. ( 8) 5~(2~Bromoacetamido) -3-ethyl-4-(o~fluorobenzoyl) -1-me hyIpyrazole, m.p. 178-181°C. , following crystallization from 2-propanol; obtained by the general method of ( 1) and (2 ) above from 16 g. of 5-amino-3-ethyl°4-( ~fluorobenzoyl) -1-methyIpyrazole and 13 g. of bromoacetyl bromide.
G. 5=(2-Azidoacetamido) -4-benzoylpyrazol.es . ( 1) -Benzoyl-l,3-dimethyl-5-(N-methyl-2-azidoacetamido) pyrazole. To a solution of 21 g. of 4-benzoyl-l,3-dimethyl-5-(N-methyl-2-bromoacetamido)pyrazole monohydrobromide in 80 ml. of N,N-dimethylformamide at room temperature is added 13 g. of anhydrous potassium carbonate and 7.0 g. of sodium azide, and the resulting mixture is stirred and heated at 6o°C for 30 minutes and is then poured into 300 ml. of ice water. The aqueous mixture obtained is extracted with dichlorometh-ane, and the extract is dried and evaporated to give solid residue of 4-benzoy 1-1 , 3-dimethyl -5-(N-methyl -2-azidoacet-amido)pyrazole; m.p. 105-107°C., following crystallization from ethyl acetate-petroleum ether. ( 2 ) 5- ( 2-Azidoacetamido) = -benzoyl- 1 , 3-dimethylpyrazole.
H s To a solution of 16 g. of ^benzoyl 2-bromoaeetamido) -1 ,3" dimethyIpyrazole hydrobromide in 75 ml. of NsN=dimethylform-amide at room temperature is added 13 g. of anhydrous potas- slum carbonate and 6.5 g. of sodium azide, and the resulting mixture is heated at 60°C. for one hour and is then poured into 250 ml. of ice water. The solid 5=(2°azidoacetamido) = -benzoyl-1,3-dimethylpyrazole that precipitates is isolated and dried; m.p. 137-139°C. , following crystallization from ethanol. (3) -Benzoy1-3-ethyl-1-methyl-5-( -meth l-2-azidoacet■=■ amido)pyrazole.
To a solution of 35 g. of -benzoyl-5-(2-bromoacet= amido) -3-ethyl-l-methylpyrazole in 75 ml. of dimethylsulfoxide at room temperature is added a solution of 14 g. of anhydrous potassium carbonate and 8 g. of sodium azide in 50 ml. of water, and the resulting mixture is stirred and heated at 60°C. for 2 hours. It is then poured into 350 ml. of ice water, and the solid 5-(2-azidoacetamido) - -benzo l-3-ethyl-l-meth lpyrazole that precipitates is isolated and dried; m.p. 122-12 °C, following crystallization from ethyl acetate-petroleum ether.
To a solution of 23 g. of the foregoing product and 12 ml. of methyl iodide in 100 ml. of NSN-dimethylformamide at 25-3 °C is added in portions 4 g. of 50$ sodium hydride in mineral oil dispersion, and the resulting mixture is stirred at 25~35°C. for 2 hours. It is then filtered and evaporated, the residue is dissolved in dichloromethanes and the dichloromethane solution is washed with water9 dried, and evaporated to give a solid residue of K-benzoyl-3-ethyl-1 -methyl-5=(N-methyl-2-azidoacetamido)pyrazole; m.p„ 12 -125°C„ , following crystallization from ethyl acetate-petroleum ether.
H. -Benzoyl-3-chloro-1-methyl-5-[2-( =toluenesulfony1oxy) = acetamido]pyrazole. A mixture consisting of 7.6 g. of 5°amino= -benzoyl~3-chloro-l-methylpyrazole, 7.2 g. of 2-(i>-toluene-sulfonyloxy)acetyl chloride, and 75 ml. of ethyl acetate is heated under reflux for one hour. Upon cooling, the resulting solution is washed with dilute hydrochloric acid and with saturated aqueous sodium bicarbonate, dried, and evaporated to give a residue of 4-benzoyl-3-chloro-l-methyl=5-[2-(£= toluenesulfonyloxy)acetamido]pyrazole, suitable for use without further purification.
I. 5~Amino-4-benzimidoyl-l,3-dimethylpyrazole. To a solution of phenyl lithium, prepared from 70 g. of bromobenzene and 5.6 g. of lithium in 300 ml. of ether, is added in portions 25 g. of 5~amino- ~cyano-l,3-dimethylpyrazole, and the resulting mixture is stirred and heated under reflux for 16 hours, cooled, and treated with 200 ml. of water. The solid precipitate obtained is isolated, drieds and extracted with 300 ml„ of warm benzene. The benzene extract is filtered, concentrated to a small volume, and cooled to giv a solid precipitate of 5~amino- »benzimidoyl~ls3"=dimethylpyrazole; <=» 63 °*
Claims (6)
1. Pyrazolo[3»4-e][l,4]diazepin-7(lH)-one compounds having the formula Ar and pharmaceutically-acceptable salts thereof; where is methyl or ethyl, Rg is an alkyl group having fewer than 4 carbon atoms or chlorine, R^ is hydrogen or methyl, and Ar is phenyl, o-fluorophenyl, or o-chlorophenyl .
2. 6, 8-Dihydro-l ,3 , 8-trimethyl- -phenylpyrazolo[3 ,4-e ] [1, ]diazepin-7( 1H) -one .
3. 4-(o-Fluorophenyl) -6 , 8-dihydro-l , 3 , 8-trimethyl-pyrazolo[3,4-e][l,4]diazepin-7(lH)-one.
4. 3-Ethyl-6, 8-dihydro-l, 8-dimethyl-4-phenylpyrazolo-[3,4-e][l,4]diazepin-7(lH)-one.
5. 4-(o-Chlorophenyl) -6, 8-dihydro-l, 3, 8-trimethyl-pyrazolo[3 ,4-e] [1,4 ]diazepin-7( lH)-one.
6. 3-Ethyl- - ( o-fluorophenyl) -6 , 8-dihydro-l-methyl-pyrazolo [3 ,4-e ] [ 1 ,4 ]diazepin-7( 1H) -one . For the Jleant* ύΐ REIKI PAWNERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82468769A | 1969-05-14 | 1969-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL34513A0 IL34513A0 (en) | 1970-07-19 |
| IL34513A true IL34513A (en) | 1972-07-26 |
Family
ID=25242076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL34513A IL34513A (en) | 1969-05-14 | 1970-05-13 | Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one compounds and methods for their production |
Country Status (8)
| Country | Link |
|---|---|
| JP (3) | JPS4911716B1 (en) |
| CA (1) | CA937236A (en) |
| DK (1) | DK136476B (en) |
| ES (1) | ES379624A1 (en) |
| HU (1) | HU162850B (en) |
| IE (1) | IE34256B1 (en) |
| IL (1) | IL34513A (en) |
| ZA (1) | ZA702161B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5249916U (en) * | 1975-10-07 | 1977-04-09 |
-
1970
- 1970-03-31 ZA ZA702161A patent/ZA702161B/en unknown
- 1970-05-13 HU HUPA001064 patent/HU162850B/hu unknown
- 1970-05-13 DK DK244870A patent/DK136476B/en unknown
- 1970-05-13 IL IL34513A patent/IL34513A/en unknown
- 1970-05-13 ES ES379624A patent/ES379624A1/en not_active Expired
- 1970-05-13 IE IE62770A patent/IE34256B1/en unknown
- 1970-05-13 CA CA082674A patent/CA937236A/en not_active Expired
-
1971
- 1971-09-18 JP JP7295771A patent/JPS4911716B1/ja active Pending
- 1971-09-18 JP JP7295671A patent/JPS4911715B1/ja active Pending
- 1971-09-18 JP JP7295871A patent/JPS496318B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IE34256L (en) | 1970-11-14 |
| JPS496318B1 (en) | 1974-02-13 |
| HU162850B (en) | 1973-04-28 |
| IL34513A0 (en) | 1970-07-19 |
| JPS4911715B1 (en) | 1974-03-19 |
| DK136476C (en) | 1978-03-06 |
| IE34256B1 (en) | 1975-03-19 |
| JPS4911716B1 (en) | 1974-03-19 |
| CA937236A (en) | 1973-11-20 |
| DK136476B (en) | 1977-10-17 |
| ZA702161B (en) | 1971-11-24 |
| ES379624A1 (en) | 1972-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4312870A (en) | Pyrazoloquinolines | |
| IL157647A (en) | 5-[2-alkoxy-5-halosulphonyl-phenyl]-1,3-(2,3-)disubstituted-1,6-(2,6)-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-ones | |
| MXPA98008897A (en) | Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them. | |
| Gomha et al. | Facile synthesis of pyrazolo [3, 4‐c] pyrazoles bearing coumarine ring as anticancer agents | |
| CA1148159A (en) | 2-aryl-pyrazolo¬4,3-c|quinolin-3-(1h and 5h)-one compounds, process for their preparation | |
| Bondock et al. | Synthesis and anticancer evaluation of some new pyrazolo [3, 4‐d][1, 2, 3] triazin‐4‐ones, pyrazolo [1, 5‐a] pyrimidines, and imidazo [1, 2‐b] pyrazoles clubbed with carbazole | |
| US3558605A (en) | Pyrazolo(3,4-e)(1,4)diazepin-7-(1h)-one compounds | |
| Rochais et al. | Synthesis of new dipyrrolo-and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1–5, GSK-3) inhibitors | |
| CA2298522C (en) | 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy | |
| US5512590A (en) | 5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics | |
| NO802326L (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED TETRAZA TRIACLES | |
| NO126325B (en) | ||
| Bondock et al. | Facile Route to Novel Pyrazolo [3, 4‐d] pyrimidine, Imidazo [1, 2‐b] pyrazole, Pyrazolo [3, 4‐d][1, 2, 3] triazine, Pyrazolo [1, 5‐c][1, 3, 5] triazine and Pyrazolo [1, 5‐c][1, 3, 5] thiadiazine Derivatives | |
| US3557095A (en) | Pyrazolodiazepinone compounds | |
| IL34513A (en) | Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one compounds and methods for their production | |
| Popov et al. | Synthesis of poly-functionalized pyrazoles under Vilsmeier-Haack reaction conditions | |
| CA1167440A (en) | 1,4,9,10-tetrahydro-pyrazolo[4,3-e]pyrido[3,2- b][1,4]diazepin-10-ones, processes for their preparation and pharmaceutical compositions containing them | |
| US3553210A (en) | 3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5(1h)-one, 7-oxide compounds | |
| US3553209A (en) | 3-methyl-8-(2-thinenyl)pyrazolo(4,3-e)(1,4) diazepin-5(1h)-one compounds | |
| US3553207A (en) | Phenylpyrazolodiazepinone compounds | |
| IE904156A1 (en) | Heterocyclic compounds and their preparation and use | |
| FI63405B (en) | FREQUENCY REFERENCE FOR THERAPEUTIC USE OF THERAPEUTIC IMMEDIATE (1,5-A) (1,4) DIAZEPINE-FOUNDATION | |
| US3544585A (en) | N'-(4-(hydroxymethyl)-5-pyrazolyl) amidines | |
| NL8002120A (en) | NEW BENZO-AS TRIAZIN DERIVATIVES AND METHOD FOR PREPARING THESE COMPOUNDS | |
| JPS5839682A (en) | Benzazepines |